SDREGN2810 + ipilimumab

SDREGN2810 + ipilimumab is a combination therapy consisting of two agents used in cancer immunotherapy. Ipilimumab is a monoclonal antibody that targets cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), an immune checkpoint receptor on T cells. By blocking CTLA-4, ipilimumab enhances the immune system's ability to recognize and destroy cancer cells[2][6][7]. It is approved for use in several cancers, including melanoma, renal cell carcinoma, colorectal cancer (especially microsatellite instability-high or mismatch repair deficient types), hepatocellular carcinoma, non-small cell lung cancer (NSCLC), malignant pleural mesothelioma, and esophageal cancer[1][2][3][6]. SDREGN2810 appears to be a code name for an investigational drug; however, no detailed public information about its mechanism of action or developer could be found in the provided sources. The combination with ipilimumab suggests it may also function as an immunotherapy agent.